Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/HMER.S50161 http://scihub22266oqcxt.onion/10.2147/HMER.S50161 C4403743!4403743!25926760     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hepat+Med 2015 ; 7 (ä): 1-10 Nephropedia Template TP {{tp|p=25926760|t=2015. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility |pdf=|usr=}}{{25926760}} gab.com Text Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility JO: Hepat Med http://www.kidney.de/pget.php?&tw=1&pmid=25926760 #FOAvip Because of the high prevalence and associated-mortality of hepatocellular carcinoma (HCC), early diagnosis of the disease is vital for patient survival. In this regard, tumor size is one of the two main prognostic factors for surgical resection, which constitutes the only curative treatment for HCC along with liver transplantation. However, techniques for HCC surveillance and diagnosis that are currently used in clinical practice have certain limitations that may be inherent to the tumor development. Thus, it is important to continue efforts in the search for biomarkers that increase diagnostic accuracy for HCC. In this review, we focus on different biological sources of candidate biomarkers for HCC diagnosis. Although those biomarkers identified from biological samples obtained by noninvasive methods have greater diagnostic value, we have also considered those obtained from liver tissue because of their potential therapeutic value. To date, sorafenib is the only US Food and Drug Administration-approved antineoplastic for HCC. However, this therapeutic agent shows very low tumor response rates and frequently causes acquired resistance in HCC patients. We discuss the use of HCC biomarkers as therapeutic targets themselves, or as targets to increase sensitivity to sorafenib treatment. Twit Text FOAVip Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility ????Hepat Med http://www.kidney.de/pget.php?&tw=1&pmid=25926760 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25926760 #FOAvip English Wikipedia <ref>{{Cite pmid|25926760}}</ref> Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility #MMPMID25926760 Ferrín G; Aguilar-Melero P; Rodríguez-Perálvarez M; Montero-Álvarez JL; de la Mata M Hepat Med 2015[]; 7 (ä): 1-10 PMID25926760show ga Because of the high prevalence and associated-mortality of hepatocellular carcinoma (HCC), early diagnosis of the disease is vital for patient survival. In this regard, tumor size is one of the two main prognostic factors for surgical resection, which constitutes the only curative treatment for HCC along with liver transplantation. However, techniques for HCC surveillance and diagnosis that are currently used in clinical practice have certain limitations that may be inherent to the tumor development. Thus, it is important to continue efforts in the search for biomarkers that increase diagnostic accuracy for HCC. In this review, we focus on different biological sources of candidate biomarkers for HCC diagnosis. Although those biomarkers identified from biological samples obtained by noninvasive methods have greater diagnostic value, we have also considered those obtained from liver tissue because of their potential therapeutic value. To date, sorafenib is the only US Food and Drug Administration-approved antineoplastic for HCC. However, this therapeutic agent shows very low tumor response rates and frequently causes acquired resistance in HCC patients. We discuss the use of HCC biomarkers as therapeutic targets themselves, or as targets to increase sensitivity to sorafenib treatment. äBiomarkers for hepatocellular carcinoma: diagnostic and therapeutic ut(epmc).pdf DeepDyve Pubget Overpricing